Apollomics announces approval of vebreltinib in china as a first-in-class treatment for gliomas with met fusion gene

Apollomics' partner in china, avistone, received approval from national medical products administration of china to expand the use of vebreltinib to the treatment of gliomas with ptprz1-met fusion gene

APLM Ratings Summary

APLM Quant Ranking